351 related articles for article (PubMed ID: 32096010)
1. Paving the way towards universal treatment with allogenic T cells.
Townsend MH; Bennion K; Robison RA; O'Neill KL
Immunol Res; 2020 Feb; 68(1):63-70. PubMed ID: 32096010
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
3. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
6. Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress.
Zhang Y; Li P; Fang H; Wang G; Zeng X
Front Immunol; 2020; 11():604915. PubMed ID: 33362790
[TBL] [Abstract][Full Text] [Related]
7. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
8. Off the shelf T cell therapies for hematologic malignancies.
McCreedy BJ; Senyukov VV; Nguyen KT
Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
[TBL] [Abstract][Full Text] [Related]
9. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
10. Challenges and opportunities of allogeneic donor-derived CAR T cells.
Yang Y; Jacoby E; Fry TJ
Curr Opin Hematol; 2015 Nov; 22(6):509-515. PubMed ID: 26390167
[TBL] [Abstract][Full Text] [Related]
11. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
13. Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
Wälchli S; Sioud M
Methods Mol Biol; 2020; 2115():407-417. PubMed ID: 32006413
[TBL] [Abstract][Full Text] [Related]
14. Using Gene Editing Approaches to Fine-Tune the Immune System.
Pavlovic K; Tristán-Manzano M; Maldonado-Pérez N; Cortijo-Gutierrez M; Sánchez-Hernández S; Justicia-Lirio P; Carmona MD; Herrera C; Martin F; Benabdellah K
Front Immunol; 2020; 11():570672. PubMed ID: 33117361
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
17. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
[TBL] [Abstract][Full Text] [Related]
18. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
Perez C; Gruber I; Arber C
Front Immunol; 2020; 11():583716. PubMed ID: 33262761
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
20. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
